Ross Kinstrie
Glasgow, SCT, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease.
Journal: Nature communications
Published: October 24, 2022
Correction: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.
Journal: Leukemia
Published: February 02, 2020
CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.
Journal: Leukemia
Published: July 08, 2019
Epigenetic Reprogramming and Emerging Epigenetic Therapies in CML.
Journal: Frontiers in cell and developmental biology
Published: May 24, 2019
Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia.
Journal: Blood advances
Published: August 24, 2016
Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition.
Journal: Cancer discovery
Published: March 01, 2016
Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia.
Journal: Scientific reports
Published: September 24, 2015
CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells.
Journal: Blood
Published: August 03, 2015
Novel drug therapies in myeloid leukemia.
Journal: Pharmaceutical patent analyst
Published: June 02, 2015
Targeting chronic myeloid leukemia stem cells.
Journal: Current hematologic malignancy reports
Published: December 25, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026